PTCT PTC THERAPEUTICS, INC.companySEC Filings & Insider Trading Activity 2026
Latest PTC THERAPEUTICS, INC. (PTCT) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 19, 2026, a 10-Q quarterly report filed on November 4, 2025, an 8-K current report filed on April 28, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for PTC THERAPEUTICS, INC. (PTCT) (SEC CIK 1070081), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: Development and commercialization of treatments for rare diseases, with focus on sepiapterin programs from Censa acquisition
- • Strategic shift: Rights Satisfaction Agreement canceled contingent net sales payments, replaced with upfront $225.1M cash payment plus up to $500M milestone payments
Risk Factors
- • Regulatory risk U.S. FDA withdrawal of Translarna NDA resubmission for nmDMD after negative feedback in January 2026
- • Geopolitical exposure Sephience marketing approvals in U.S., EEA, Japan, Brazil with $111.2M 2025 net revenues, but country-specific pricing/licensing risks
Management Discussion & Analysis
- • Revenue impact: upfront $1.0B from Novartis Agreement in Jan 2025, with potential $1.9B milestones, 40% US profits share, tiered double-digit royalties ex-US
- • Operating cash flow $711.2M in 2025 vs $(107.7)M in 2024 and $(158.4)M in 2023, driven by Novartis upfront and clinical/commercial spend
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New director/officer trading arrangements under Rule 10b5-1 adopted Sept 2025 for sales up to 259,346 shares, latest expiring March 2027
- • Updated insider trading compliance risk reflecting expanded use of Rule 10b5-1 plans to manage equity sales and tax obligations
Annual Reports Archive10-K
AI-powered analysis of PTC THERAPEUTICS, INC. (PTCT) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of PTC THERAPEUTICS, INC. (PTCT) 10-Q quarterly reports filed with SEC EDGAR.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $698.8M | $937.8M | $806.8M | $1.7B |
| Operating Income | -$447.4M | -$439.5M | -$302.6M | $866.9M |
| Net Income | -$559.0M | -$626.6M | -$363.3M | $682.6M |
| Op. Margin | -64.0% | -46.9% | -37.5% | 50.1% |
| Net Margin | -80.0% | -66.8% | -45.0% | 39.4% |
| Balance Sheet | ||||
| Total Assets | $1.7B | $1.9B | $1.7B | $2.9B |
| Equity | -$347.1M | -$818.6M | -$1.1B | -$205.3M |
| ROE | 161.1% | 76.6% | 33.1% | -332.5% |
Source: XBRL financial data from PTC THERAPEUTICS, INC. (PTCT) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 28, 2026 | — | — | — |
8-K | Mar 25, 2026 | — | — | — |
8-K | Feb 19, 2026 | — | — | |
10-K | Feb 19, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 12, 2026 | — | — | |
8-K | Jan 12, 2026 | — | — | |
8-K | Dec 29, 2025 | — | — | |
10-Q | Nov 4, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 6, 2025 | Mar 31, 2025 | — | |
10-K | Feb 27, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | Apr 25, 2024 | Mar 31, 2024 | — | |
10-K | Feb 29, 2024 | Dec 31, 2023 | — | |
10-Q | Oct 26, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | Apr 27, 2023 | Mar 31, 2023 | — | |
10-K | Feb 21, 2023 | Dec 31, 2022 | — | |
10-Q | Oct 27, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 4, 2022 | Jun 30, 2022 | — | |
10-Q | May 3, 2022 | Mar 31, 2022 | — | |
10-K | Feb 22, 2022 | Dec 31, 2021 | — | |
10-Q | Oct 28, 2021 | Sep 30, 2021 | — | |
10-Q | Jul 29, 2021 | Jun 30, 2021 | — |
Frequently Asked Questions
What are the latest PTCT SEC filings in 2026?
PTC THERAPEUTICS, INC. (PTCT) has filed a 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on April 28, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did PTCT file its most recent 10-K annual report?
PTC THERAPEUTICS, INC. (PTCT) filed its most recent 10-K annual report on February 19, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view PTCT 10-Q quarterly reports?
PTC THERAPEUTICS, INC. (PTCT)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every PTCT 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has PTCT filed recently?
PTC THERAPEUTICS, INC. (PTCT)'s most recent 8-K was filed on April 28, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find PTCT insider trading activity (Form 4)?
SignalX aggregates every PTCT Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does PTCT file with the SEC?
PTC THERAPEUTICS, INC. (PTCT) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new PTCT filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for PTC THERAPEUTICS, INC. (PTCT).
What is PTCT's SEC CIK number?
PTC THERAPEUTICS, INC. (PTCT)'s SEC CIK (Central Index Key) number is 1070081. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1070081 to look up all PTCT filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find PTCT return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from PTC THERAPEUTICS, INC. (PTCT) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of PTC THERAPEUTICS, INC. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 45+ filings.